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1. Introduction 
In 1988 Starzl challenged the consensus view from 1983 that only a small percentage of 
patients with alcoholic liver disease (ALD) would be expected to meet the criteria for 
transplantation (National Institute of Health [NIH], 1984). Starzl and his team reported the 
successful liver transplantation (LT) of patients with ALD, and suggested that few patients 
returned to alcohol after liver transplantation (Starzl et al., 1988). Since then ALD has become 
one of the most common indications for LT in adults. However, despite this success, there 
remains significant debate and controversy regarding the indication, as several studies over 
time have shown that the public may not be supportive of the idea of allocating a limited 
resource, such as the liver graft, to patients with ALD. This chapter will discuss the pre-
transplant evaluation of patients with ALD, the debate over the treatment of acute alcoholic 
hepatitis, and the outcome of LT for ALD, including the issue of relapse. Finally, certain ethical 
concerns such as the use of living donors and future challenges will be analyzed. 
2. Pre-transplant evaluation of patients with ALD 
Patients with ALD, as part of their pre-transplant evaluation, are assessed by a multi-
disciplinary team consisting of hepatologists, surgeons, social workers and psychiatrists. 
The decision to list the patient depends on the status of the liver disease, which is expressed 
in most centers by the Model for End-stage Liver Disease (MELD) score. This is a relatively 
objective measurement of the patients’ degree of liver disease by using the patient’s 
bilirubin, creatinine and INR serum values to calculate the MELD score. The latter is 
empirically capped at 40 and represents a continuous variable ranging from 6 to 40 and it 
has proven to be highly accurate in assessing 3 month mortality once a cirrhotic patient is on 
the waiting list (Kamath et al., 2001). There is however the assertion that ALD patients may 
be under-referred for LT in the United States (Kotlyar et al. 2008). This may be because ALD 
may represent a negative determinant for many physicians to refer patients for LT, or there 
may be a lack of recognition of the contribution of excessive alcohol consumption to liver 
failure in the community. One study identified patients with liver failure in whom alcohol 
consumption was not recognized or acknowledged by the referring physicians (Day et al., 
2008). It is not clear whether this was a purposeful omission or a genuine lack of recognition, 
but it does underscore the need for careful attention to the presence of alcoholic disorders in 
patients with liver failure.  
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2.1 Abstinence prior to LT for ALD 
Patients with ALD undergo the standard pre-transplant evaluation, whose goal is to 
determine the suitability of the potential candidate to undergo the LT, as well as the urgency 
with which this has to be performed, based on the severity of the liver disease. Specifically 
for patients with ALD the issue of abstinence is critical in making these determinations. The 
apprehension that candidates for LT with ALD are likely to relapse and cause damage to the 
graft, makes it important to select those patients with the lower risk of relapse. To ensure 
this formal pretransplant substance misuse evaluations are required, including a broad 
psychosocial and substance abuse assessment. Factors analyzed include the pattern of 
previous alcohol use, diagnosis of alcohol use disorder, length of abstinence and features 
that would indicate a higher risk of future return to alcohol consumption (Dobbels et al., 
2009; Gedaly et al., 2008). People judged suitable for LT are patients with severe end-stage 
liver disease, a clear understanding of the risks and benefits involved in the procedure, and 
a favorable psychiatric profile including acceptance of their alcoholism and factors in their 
family and social network that would ensure post-transplant sobriety. 
Pretransplant abstinence offers the advantages of allowing the liver disease an opportunity to 
stabilize, as well as testing the patient’s commitment and resolve to proceed with this 
treatment. The transplant team with the support of the psychiatrists and the abuse specialists 
has the ability during that period to evaluate the patient and the presence of a support 
network, as well as monitor their resolve through frequent visits, as well as unannounced 
testing. There remains significant debate regarding the extent of the required abstinence 
period. Specifically, the vast majority of transplant centers (85%) in the United States require 6 
months of abstinence prior to transplantation, with a significant number expecting the patients 
to sign a formal contract (Everhart & Beresford, 1997). This view was changed in 2005, 
following the UNOS and French Consensus Conference on LT, as there was not an agreement 
in the literature regarding the 6 month sobriety period (Mathurin, 2005).  
People in favor of the 6 month abstinence period cite 3 main advantages. First, the period of 
pretransplantation abstinence may allow liver recovery, even to the extent of a LT becoming 
unnecessary, with one study showing significant improvement within 3 months (Veldt et al., 
2002). Second, it can help identify those patients unable to abstain, and thus more likely to 
relapse after the LT. This cannot happen reliably when a patient presents with decompensated 
liver disease, as “death-bed repentance”, no matter how genuine, may not accurately reflect 
future intentions. Finally, the time of abstinence can and should be used for intensive 
rehabilitation and treatment for the alcohol dependence, as relapse is more frequent within the 
first year after quitting alcohol. Others have questioned the need for an arbitrary period of 
abstinence pre-LT. All agree that the 6 month period is not based on prospectively gathered 
data, but rather on custom and practice (Neuberger et al., 2002). The main argument against 
the enforced time period of abstinence has been that it may be more of a selection method 
favored by insurance companies, rather than an effective predictor for post-transplant 
abstinence. Some of the key studies in the field have advocated that full psychosocial 
assessment as part of the pretransplant evaluation of the ALD patient may be more important 
than a universal application of a 6 month abstinence rule (Pfitzmann et al., 2007). Additionally, 
these studies have shown that the frequency of both minor and harmful drinking is frequent in 
the first 5 years after LT, despite careful pre-transplant assessment, although it is equally 
useful to distinguish between harmful drinking and “slips” (DiMartini et al., 2006; Pfitzmann 
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et al., 2007). Setting a fixed time period for pre-LT abstinence as a rigid rule, fails to take into 
account the multiple clinical and psychosocial variables of ALD patients. Patients with ALD 
are not immune from hepatocellular carcinoma (HCC), and as such cannot have an arbitrary 
waiting time period placed on them, as in that case there is the real danger of the HCC getting 
outside Milan criteria, and thereby precluding any chance of a LT. This is not to say that there 
should not be a proper evaluation of the severity of the alcohol dependence in these patients, 
or measures taken to achieve sustained abstinence and prevent relapse; however, in order to 
reach a consensus on a period of abstinence prior to the LT, large, multicentric, randomized 
longitudinal prospective studies are needed to analyze the decision making methods carefully 
and completely (Beresford & Everson, 2000). 
The question of the 6 month abstinence period prior to a LT is only part of the effort to 
identify predictors of post-LT relapse. In addition to the studies supporting that the length 
of sobriety is a strong predictor of recidivism, there are others reporting that patients with a 
DSM-IV diagnosis of abuse had a lower relapse probability than those with alcohol 
dependence (DiMartini et al., 2006; Karim et al., 2010). DiMartini et al. showed that variables 
such as alcohol dependence, short length of sobriety, family history of alcohol consumption 
and the use of other substances identified patients with a major risk of relapse (DiMartini et 
al., 2010). Despite that there are studies showing that pre-LT behavior is a poor predictor of 
relapse, or that other variables such as demographic, family and social ones come into play 
(De Gottardi et al., 2007; Foster et al., 1997; Kelly et al., 2006; Pfitzmann et al., 2007). Overall, 
this multitude of often competing possible predictors of recidivism, further stresses the need 
for an accurate stratification of potential candidates to identify those most likely to remain 
abstinent, and thus benefit the most from a LT. 
2.2 Comorbidities associated with ALD 
There is a significant number of comorbidities among patients with ALD which ultimately 
may limit their suitability for LT, unless properly addressed. Some of these comorbidities may 
be a direct effect of alcoholism, or they may be medical conditions commonly occurring in 
alcoholics. Patients with alcoholic cirrhosis may have alcohol related heart disease, such as 
alcoholic cardiomyopathy, in addition to the cirrhotic cardiomyopathy that is attributed to 
cirrhosis itself, and this may be related to the total lifetime use of alcohol (Urbano-Marquez et 
al., 1989). Alcoholic cardiomyopathy has specific diagnostic criteria and is associated with 
active alcohol intake. For that reason interventions that would lead to alcohol cessation would 
also prevent progression to cardiac failure. Additional medical comorbidities include 
neurologic disease ranging from myopathy to fixed deficits, with the latter being at times hard 
to differentiate from the hepatic encephalopathy that is associated with cirrhosis and can be 
reversible following LT (Keefe, 1997). Chronic pancreatitis and malnutrition are other 
problems commonly seen in these patients, whereas one cannot ignore the coexistence of other 
liver disease, such as chronic hepatitis C virus (HCV) infection or hepatocellular carcinoma 
(HCC), which can affect the urgency of LT, and especially the overall prognosis. 
2.3 Acute alcoholic hepatitis 
Acute alcoholic hepatitis (AH) represents a treatment dilemma for the medical team, as it 
may occur in patients with previously normal liver or with established cirrhosis. Patients 
with a previously normal liver present an opportunity, from a technical standpoint, as the 
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liver transplantation is significantly easier with the absence of the trademarks of end-stage 
liver disease, such as portal hypertension (Figure 1 a, b).  
 
 
Fig. 1. a, b: Different types of livers encountered in patients with alcoholic liver disease. (a) 
This patient has acute alcoholic hepatitis on top of previously established cirrhosis. The 
hepatectomy stage of the LT is much more challenging in this patient. (b) This patient has 
acute alcoholic hepatitis without any previous evidence of cirrhosis, with the liver revealing 
some edema, but no cirrhosis. 
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Unfortunately, in the severe form, even with maximal medical treatment, there is a 40-50% 
mortality within 1 month after diagnosis (Dureja & Lucey, 2010). This very high mortality, 
despite the organ shortage, has led to many advocating LT for that subset of patients who 
have failed medical treatment. To date, only corticosteroids and pentoxifylline are 
considered to potentially improve short-term survival, although the results of meta-analysis 
remain controversial (Imperiale et al., 1990; Mathurin et al., 2011). Currently, the majority of 
transplant centers are reluctant to offer LT for patients with acute AH, although there is an 
effort to identify that subset of patients that will fail medical treatment with corticosteroids 
and likely benefit the most from LT. Experience has been mixed regarding transplantation 
for these patients, although there are some encouraging new studies, where strict selection 
can lead to favorable results, both in terms of survival, as well as in terms of relapse (Castel 
et al., 2009; Tome & Lucey, 2003). One of these studies was a European multicenter study 
about a carefully selected group of patients suffering from their first episode of severe AH 
and for whom medical treatment had failed. They had received a favorable psychosocial 
assessment and had excellent intermediate survival and low frequency of significant 
drinking after LT (Castel et al., 2009). Based on these results, transplant groups on both sides 
of the Atlantic have argued in favor of placement on the LT waiting list of patients with life-
threatening AH who meet criteria. 
3. Outcome of LT for ALD and ethical issues 
3.1 Outcome of LT for ALD 
The overall survival of patients who underwent LT for ALD is statistically comparable to 
that of patients who underwent LT for other indications. Data from the European Liver 
Transplant Registry 2008 revealed 1-, 5-, and 10-year patient survival rates for ALD of 96%, 
88% and 76% respectively, as compared to 97%, 80% and 72% for patients with other 
indications (European Liver Transplantation Registry [ELTR], 2008). Similar survival rates 
have been reported for ALD patients in the US after LT: 92% at 1 year, 86% at 3 and 5 years 
and 76% at 9 years (Bhagat et al., 2009). It has been shown that patients with ALD had 
similar patient and graft survival rates, if not better in some cases, compared to those of 
patients undergoing LT for other indications (Dumortier et al., 2007; Mutimer et al., 2006; 
Romano et al., 1999). In a “perfect” world patients would have a single aetiology for their 
end-stage liver disease, unfortunately in the real world patients may undergo LT for ALD in 
the presence of other comorbidities, which can significantly affect the result. The most 
common is HCV, where there have been data of a more rapid progression of the liver 
disease in immunocompetent patients with the combination of ALD and HCV (Cromie et 
al., 1996; Pessione et al., 1998). However, other, more recent studies have shown that 
patients transplanted for ALD  plus HCV had a better survival than patients with HCV 
alone and similar survival to those with ALD alone (Aguilera et al., 2009). This could be 
partly explained by the greater use of antiviral treatment in patients with HCV and ALD, as 
they were younger than the HCV alone patients. Furthermore, data from the European Liver 
Transplantation Registry have shown similar post-LT survival rates between patients with 
ALD and ALD plus a viral etiology (HCV and HBV), although patients with ALD plus HCV 
had a significantly shorter survival compared to those with ALD plus HBV infection (Burra 
et al., 2010). These data support the notion that ALD represents a good indication for LT, 
even in the presence of hepatitis virus infection. 
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Regarding long-term morbidity and survival in patients with ALD, there appears to be an 
effect from a high prevalence of medical comorbidities, including de novo cancers. In one 
study of a group of patients undergoing LT for ALD, 5 year graft and patient survival were 
significantly lower than non-alcoholics undergoing LT, mainly due to cardiorespiratory, 
cerebrovascular and neoplastic problems (Jain et al., 2000). When compared to patients 
receiving LT for other indications, those transplanted for ALD are at a greater risk of de 
novo malignancy, and especially aerodigestive cancers possibly due to the chronic alcohol 
use (Oo et al., 2005; Watt et al., 2009). These comorbidities are associated with worse 
survival (Bellamy et al., 2001; Duvoux et al., 1999). These studies do not show an association 
between new-onset cancers and alcoholic relapse. An important factor may be the high 
prevalence of chronic heavy tobacco use in this population, in combination with the 
immunosuppression. This presents the question of whether patients with ALD require 
specific surveillance programs for de novo tumours after LT. Also, if the link between 
tobacco use and death from either cancer or cardiovascular disease holds true, then an 
obvious way to improve post-transplant health is through the promotion of smoking 
cessation, especially in LT recipients with alcoholism. 
3.2 Impact of recidivism on survival after LT for ALD 
Not unexpectedly, better survival rates were observed for patients that remained abstinent 
after LT than those who returned to alcohol use. Still in trying to identify the impact of 
recidivism on survival after LT, first we have to overcome the problem of a lack of a 
commonly accepted definition and the fact that the reported rates of recidivism vary widely 
at different follow-up periods post-LT. In one of the better prospective studies, DiMartini et 
al., showed that 22% of patients had used some alcohol by the first year after LT and 42% 
had a drink by 5 years (DiMartini et al., 2006). By 5 years, 26% drank at a heavier use pattern 
and 20% in a frequent pattern. In another prospective study by DiMartini et al., there were 
five different patterns of alcohol consumption identified, based on the time of relapse and 
the subsequent pattern (DiMartini et al., 2010). Approximately 80% of the patients either did 
not drink or consumed only small amounts rarely. Among the remaining 20%, there were 3 
patterns of harmful drinking, varied according to the time of relapse and the consumption 
of alcohol (sustained, heavy use or subsequently modified drinking). These data were 
similar to the retrospective data from Tang et al., who found harmful drinking in 16% of the 
patients (Tang et al., 1998). The problem of identifying a commonly-accepted definition for 
recidivism and the prevailing rates is made more difficult by the fact that most of these 
studies are based on data obtained through self-report questionnaires, interviews with 
patients and/or family members, or even retrospective analysis of routine screening tests. In 
all of this there is an apparent risk of underestimation. 
However, there is disagreement on the impact of recidivism on post-transplant survival. 
Specifically, there have been studies showing no significant impact on survival rates 
(Burra et al., 2003; Gerhardt et al., 1996). These have been contradicted by other studies 
reporting 5- and 10-year survivals of 69% and 20% respectively in patients with alcohol 
relapse following LT, and the argument that attention needs to be paid to the different 
patterns of relapse, rather than the overall rate (DiMartini et al., 2006). It does appear that 
the long-term survival of patients who resume heavy drinking is lower compared to those 
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who remain abstinent or have minor slips (Cuadrado et al., 2005; Pfitzmann et al., 2007). 
Interestingly enough, a significant factor for the decreased survival appears to be an 
association with developing malignancies, rather than recurrent end-stage liver disease. 
The influence of slips on LT outcome remains unclear, but there is the general perception 
that, although a slip should be considered an adverse event, it is unlikely to cause harm if 
it does not lead to a full-blown relapse (Cuadrado et al., 2005; Pfitzmann et al., 2007). One 
area where clinicians should pay particular attention to alcohol recidivism is when it is 
combined with concomitant HCV infection, since it may exacerbate the liver damage with 
rapid progression to cirrhosis and graft loss (Bellamy et al., 2001; Neuberger et al., 2002; 
Tome & Lucey, 2003). This can often lead to a late onset of acute or chronic rejection, 
whose management can be a nightmare in the patient with HCV recurrence (which is the 
vast majority of patients).  
A question closely related to the effect of recidivism on survival after LT for ALD, is that of 
the quality of life after the LT. In a study in the UK of patients undergoing LT for ALD over 
a 10-year period, it was seen that overall in the long term at least 50% of the patients will 
drink again at some time post-LT, although at lower levels of alcohol intake than before the 
transplant (Perreira et al., 2000). The group at greatest risk for harmful drinking appears to 
be the patients with the most predictive factors for relapse, and thus the group that would 
benefit the most from professional counselling. Even so, the overall quality of life after LT 
for ALD, based on three different questionnaires, is high and in general similar to the level 
expected in the general population. When everything is put together regarding the issue of 
recidivism after LT for ALD, the challenge is the need for improved methodology and tools 
in monitoring post-transplantation abstinence, in order to better evaluate the effect of 
relapse. Ultimately, the question is critical, as it raises the issue of proper stewardship of a 
limited resource for society. 
3.3 Cost-effectiveness of LT for ALD 
As liver transplantation has not really been the subject of a randomized controlled trial, 
there is some uncertainty regarding the magnitude of the benefit and cost-effectiveness 
for specific patient groups. In an attempt to answer this question a study from England 
and Wales attempted an economic evaluation of liver transplantation in that area 
(Longworth et al., 2003). Cost-effectiveness was measured using incremental cost per 
quality-adjusted life years (QALY; commonly referred to as cost-utility analysis). The 
results of a comparison group, representing experience in the absence of LT, are estimated 
using a combination of observed data from patients waiting for transplant and published 
prognostic models. The analysis was limited to three disease groups for which prognostic 
models were available at the beginning of the study, one of which was the group of 
patients with ALD. Overall, a higher proportion of patients with ALD were assessed for a 
transplant but not placed on the waiting list. The estimated gain in quality-adjusted life-
years from transplantation was positive for each of the disease groups. The mean 
incremental cost per quality-adjusted life-year from time of listing to 27 months was 
€54,000 (€13,500 to €93,500). The study showed that LT increases survival and health-
related quality of life of ALD patients, although the cost-effectiveness estimates within 
that 27 month period were poorer for patients with ALD than for patients with PBC or 
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PSC. The authors suggested that this may reflect the cost of the higher number of ALD 
patients assessed for each transplant. 
3.4 Ethical issues 
The indication of ALD for LT is unlike many of the others as it involves the proper use of a 
scarce resource for patients with a potentially “self-inflicted” disease. Some have argued 
that since alcohol dependence as an “addiction” carries a neurobiological and a genetic 
component, then it may be more appropriate to treat it more as a medical condition. This 
does not answer the problem fully, as what matters is the outcome and if we accept that self-
control has no role in the management of alcoholism then relapse would be all but a 
certainty. Others have challenged the ethics of the “6-month abstinence” rule, based on lack 
of evidence making it an arbitrary decision (Everhart & Beresford, 1997). Studies have found 
that although neither the presence of histological alcoholic hepatitis in the explant, nor any 
history of drinking within 6 months correlated with subsequent relapses (Tome et al., 2002; 
Wells et al., 2007). Against this background of conflicting data, there is a lack of consensus 
from country to country regarding the timing and suitability of patients with ALD for LT. 
One has to consider whether rules such as the “6-month” one represent an attempt towards 
an ethical approach to patient selection for LT, or whether they are a matter of practicality. 
For example, in the United States, the evaluation process usually results in the presentation 
of a comprehensive clinical and psychosocial assessment to the transplant program’s 
selection committee. When the selection committee decides to recommend transplantation, 
the approval of the third party payer is necessary before the patient is placed on the waiting 
list. The 6-month rule has been widely adopted by the US insurance industry, without 
adequate data, leading to anecdotal reports of the difficult decisions involved (Boren, 1994). 
There are certain lessons that can be drawn regarding sobriety and prognosis after LT for 
ALD, which may have more validity than simply following the 6-month rule. Specifically, 
no single measure is a reliable prognosticator for future relapses into harmful drinking after 
transplantation, and although the duration of abstinence has been associated with 
subsequent drinking, it is an imprecise prognostic tool. Furthermore, there is more value in 
a careful evaluation by a trained addiction specialist with a special interest in transplant 
medicine, with such a psychosocial assessment helping determine the risk of relapse into 
significant alcohol abuse, but not with an absolute certainty. Finally, when all is said and 
done, the severely ill patient who has been drinking recently, but has other favorable 
prognostic indicators with respect to post-transplant behavior, represents a very difficult 
question for any transplant program.  
Another issue is that since the need to restrict access to LT for patients with ALD is based on 
the donor shortage, then it could be argued that these recipients should be held to different 
standards when there is the possibility of a living donor. The answer to this question should 
still relate to the outcome and long-term results of LT for this group of patients, as no matter 
how willing the living donor may be, it must be made certain that the benefit to the recipient 
is worth the risk to the donor. Consideration of ALD patients as recipients for Living Donor 
Liver Transplantation (LDLT) has raised similar issues as those seen with cadaveric 
donation for these patients. Since most living donors are closely related to the recipient, they 
have watched the progression of ALD in the recipients over time and many may not regard 
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the pathogenesis of ALD as totally unavoidable. This would result to donors seeing 
recipient relapses with alcohol, no matter how frequent or clinically significant, as 
ingratitude. Thus, for every patient with ALD being considered for LDLT there are 
individual conditions and relationships, which dictate significant less tolerance with alcohol 
relapse in LDLT compared to cadaveric donation. 
The answer to many of these concerns has been the utilization of the 6 month abstinence 
rule by most programs. Notwithstanding the shortcomings of this rule regarding its 
predictive capacity that have been described elsewhere in this chapter, there are also 
certain issues unique to LDLT that may limit its use. Specifically, with a cadaveric LT there 
is the “luxury” of waiting given the organ shortage, and so that period can be used to test 
the abstinence and intervene; in LDLT the biggest advantage is the short preparative 
period and waiting time needed, something which would be negated by the strict use of 
the 6 month rule. Additionally, there are several Asian countries where, because of 
religious considerations, LDLT is the main type of LT, as cadaveric donation is limited or 
nonexistent. Thus, in these countries patients with ALD may have limited options. These 
two points are not meant to suggest that patients with ALD should be able to proceed with 
LDLT without addressing the issue of alcohol abuse and the possibility of recidivism, as 
that would be a disservice to the gift of the donor. A study by Hwang et al. from the Asan 
Medical Center in Korea of patients with ALD undergoing LDLT concluded that the 
pretransplant abstinence seemed to be beneficial and that for ethical reasons the 6 month 
abstinence rule should be strictly observed in LDLT (Hwang et al., 2006). When 
considering the ethical aspects of living organ donation, it is certainly reasonable to 
exclude recipients with significant factors for relapse. Also, we need to consider the unique 
aspects of the donor-recipient relationship, similar to those seen in the case of LDLT for 
patients with HCC. Along these lines a factor that may help is that a very close relationship 
between the donor and the recipient may be critical in preventing alcohol relapse or at least 
an escalation to significant alcohol abuse. The same study from South Korea found 3- and 
5-year relapse rates of 20% in these patients undergoing LDLT for ALD, lower than many 
of the studies with cadaveric LT (Hwang et al., 2006). This issue cannot be simply ignored 
as in Korea, for example, at the Asan Medical Center 134 LDLTs had been performed by 
2003, of which only four were for ALD (Moon & Lee, 2004). Although the actual prevalence 
of ALD in S. Korea may not be known, it is thought that 6% of patients with cirrhosis have 
ALD. This means that the trends are changing, as the 20-year vaccination program for 
Hepatitis B virus has reduced the incidence of the disease in the population, there is a 
gradual increase in alcohol consumption which will eventually lead to a higher need for 
LDLT for patients with ALD. 
4. Future challenges 
4.1 Psychosocial assessment 
Evaluating the role of LT in the treatment of patients with ALD is a work in progress as 
significant challenges remain. Chief among them is the need for improved psychometric 
tools and assessments that would be able to predict with greater accuracy the pattern of 
alcohol use after transplant and the effect of that on the liver graft. This could lead to  
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more targeted interventions with higher likelihood of success. A number of predictive 
tools have been considered as part of the assessment. The University of Michigan 
Alcoholism Prognosis Scale examines a number of psychosocial domains with a higher 
score suggesting increased stability leading to improved prognosis and Lucey et al. have 
suggested this broad-based tool as a useful alternative to the fixed pre-LT abstinence 
period (Lucey et al., 1997). Other tools include the alcohol abstinence self-Efficacy Scale 
which rates an individual’s ability to self-determine in the context of relapse precipitants 
(DiClemente et al., 1994). Although it has shown good reliability and validity in alcohol 
treatment settings, it has yet to be proven in the liver transplant setting. Beresford, an 
addiction psychiatrist from the University of Michigan, who introduced the concept of 
psychosocial assessment of ALD transplant candidates, alerted the transplant community 
to the clinical insights into the factors involved in maintaining sobriety reported in the 
addiction literature (Beresford, 1994). Based on the studies of Vaillant and of Strauss and 
Bacon, he constructed a panel of negative prognostic factors that he used to assess 
prospective ALD patients as candidates for LT (Strauss & Bacon, 1951; Vaillant, 1995). 
These included psychiatric comorbid conditions, such as uncontrolled polysubstance 
abuse or unstable character disorder, a history of many failed rehabilitation attempts, 
social isolation as shown by lack of a fixed employment and living alone without a spouse 
or companion.  
All of this has led to psychosocial assessment becoming part of the norm in liver transplant 
centers, where the use of agreed clinical guidelines and candidate selection criteria offer the 
assessment team a framework upon which to base complex decisions and an opportunity to 
explain the assessment and decision to the patient. It also allows transplant centers the 
opportunity to audit their selections and outcomes against accepted listing criteria. These 
observations, together with those by DiMartini documenting the five patterns of alcohol use, 
need validation in a large prospective cohort, and if successful can help clinicians identify 
tailored monitoring and interventions. Behavioral and pharmacological therapies may be 
necessary and helpful, but it is essential that they are individualized and that the support 
required is discussed and agreed upon with the candidate and their support system 
(DiMartini et al., 2010). 
4.2 Genetic element of ALD 
Also, further data are needed to clarify the element of genetic predisposition in alcohol 
abuse, as this too could help identify people at greater risk. Recent high-throughput 
technologies, such as micro arrays, genomics and proteomics have led to novel concepts in 
our understanding of several liver pathologies (Decaciuc et al., 2004; Seth et al., 2006). 
Application of these technologies has identified novel pathways that could not have been 
discovered using traditional methods and opened up several lines of investigation for 
understanding the mechanism involved in alcohol-mediated liver injury. Hepatic gene 
profiling using DNA micro arrays are reported from animal models of ALD and human 
ALD (Decaciuc et al., 2004; Seth et al., 2006). The ALD transcriptome profile is dominated by 
alcohol metabolism and inflammation related molecules, thus differing from other liver 
diseases (Seth et al., 2003). Additionally, several functional groups of genes showed similar 
qualitative and quantitative changes also in rodents as a result of chronic alcohol exposure 
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regardless of the type of array platform (Decaciuc et al., 2004). This finding shows the 
existence of common mechanisms of alcohol effect on the liver across species.  
In the past, genetic studies in ALD have focused on genes involved in alcohol metabolism 
(ADH, ALDH, CYP2E1), oxidative stress (GST, superoxide dismutase), endotoxin (TNF-a, 
CD14, TLR4), cytokines (IL-10), immune (cytotoxic T-lymphocyte antigen-4) and fibrosis 
(collagen, MMPs, osteopontin, TGF-b) and have been extensively reviewed (Stickel & 
Osterreicher, 2006). All appear to have an effect, but to date the search for single nucleotide 
polymorphisms (SNPs) in a hypothesis-driven candidate gene approach has been rather 
disappointing in identifying risk factors for ALD. Some of the reasons have been that most 
of the studies involved have either lacked statistical power due to small sample size, or 
investigated polymorphisms in a single or a few candidate genes or were subject to 
population stratification, Type 1 and 2 errors, or have failed to account for factors such as 
obesity and the confounding effect of Non-alcoholic steatohepatitis (NASH). Susceptibility 
to ALD, like most other multifactorial complex diseases, is controlled by a number of genes, 
each of which makes its own contribution. Therefore, what is needed is a genome-wide 
approach, in carefully designed large studies in order to identify various degree of risk 
genetic variants associated with ALD. The lack of an a priori hypothesis has helped Genome 
Wide Association (GWA) technologies yield successful outcomes in a variety of several 
common liver diseases (Karlsen et al., 2010; Kolleritis et al., 2009; Romeo et al., 2008). 
Advantage should also be taken of the understanding gained from research in other liver 
diseases, such as NASH, that show increasing parallels with ALD development. Recent 
advances in newer technologies enabling genome wide search for millions of SNPs, whole 
genome sequencing, global epigenetic profiles, and non-coding regulatory elements 
(miRNA) are the future research areas to construct the architecture of ALD and identify 
ways to predict and intervene in its progression. In these times of financial turmoil, a global 
well-coordinated effort is required to invest in future research to provide answers for a 
problem common in all different countries. 
5. Conclusion 
Liver transplantation has become over the last few decades one of the main treatments for 
advanced ALD. However, in order to optimize the results of this treatment, as well as fully 
establish its societal acceptance, it is imperative that careful patient selection takes place and 
that attention is paid not only to the peri-operative but also to the pre- and post-transplant 
periods. We need to stratify ALD potential transplant candidates according to the risk of 
relapse. Unfortunately, as we have seen in this chapter, to date the results reported from 
different studies are mostly inconclusive regarding the evaluation of predictive factors for 
alcoholic relapse after LT. Also, a defined pre-LT abstinence period for ALD candidates for 
transplantation appears to be justified, both as a way to ensure compliance, as well as an 
opportunity to effect some interventions to possibly recover liver function to the extent that 
a LT might not be needed. Even so, there are no strong data supporting the 6 month 
abstinence rule, and that means that we need to reach a consensus on this specific issue by 
conducting longitudinal, prospective studies. Just as important is the need to avoid the ease 
that strict “yes or no” rules and regulations offer (such as the 6 month rule) and concentrate 
more on creating and using improved psychomotor tools and assessments that will allow us 
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to better evaluate and help these patients. The question of the definition of alcohol relapse is 
another area where further studies are needed. The reason is that although a number of 
patients return to some degree of alcohol use after LT, recidivism leading to liver disease 
threatening the graft is uncommon. Additionally, post-LT surveillance programs for the 
early detection of cardiovascular problems and de novo malignancies are also needed, given 
the apparent higher prevalence in this population. To fully achieve this, patients with ALD 
need to be evaluated and followed by a team of professionals, including internists, surgeons, 
hepatologists, psychiatrists and social workers who will be able to fully address their 
complicated needs. 
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